Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2026

The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $3.13 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing use of highly emetogenic chemotherapy, rising awareness of treatment side effects, availability of advanced antiemetic drugs, expansion of oncology treatment programs, improved clinical guidelines for cinv management.

The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing demand for next-generation antiemetics, rising adoption of personalized antiemetic therapy, expansion of outpatient chemotherapy services, growing focus on adherence to treatment protocols, advancements in sustained-release formulations. Major trends in the forecast period include increasing adoption of combination antiemetic regimens, rising use of long-acting cinv drugs, growing focus on patient-centric treatment approaches, expansion of preventive cinv management protocols, enhanced emphasis on quality-of-life outcomes.

The rising prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced nausea and vomiting (CINV) market in the coming years. Cancer is a condition in which abnormal cells grow uncontrollably and spread to other parts of the body. As the number of cancer cases continues to increase, there is a growing need to develop more effective and targeted antiemetic therapies to manage CINV, a common and distressing side effect of chemotherapy. This increased emphasis on CINV management has contributed to deeper insights into its underlying mechanisms and the development of novel treatment options. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization dedicated to cancer prevention and control, approximately 1.9 million new cancer cases (around 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) were projected in the United States in 2023. Therefore, the increasing prevalence of cancer is fueling the growth of the chemotherapy-induced nausea and vomiting (CINV) market.

Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are concentrating on innovative product developments, such as fixed intravenous antiemetic formulations, to gain a competitive advantage. A fixed intravenous antiemetic refers to a standardized dose of medication delivered via intravenous administration to prevent or manage nausea and vomiting, commonly used in chemotherapy and surgical settings. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company specializing in branded, generic, and over-the-counter products, launched AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination developed to prevent CINV. This formulation combines netupitant and palonosetron to address both acute and delayed phases of nausea and vomiting. It provides single-dose convenience, improved complete response rates, and enhanced quality of life for cancer patients, with clinical studies indicating particular effectiveness in individuals receiving highly emetogenic chemotherapy.

In January 2023, Helsinn Healthcare SA, a Switzerland-based global cancer supportive care company, entered into an exclusive partnership with Immedica Pharma to commercialize its oncology supportive care products across key European markets. This partnership is intended to broaden patient access to established cancer supportive therapies, strengthen Helsinn’s commercial presence in the region, and expand Immedica’s portfolio with proven treatments that address significant unmet needs in cancer care. Immedica AB is a Sweden-based pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care.

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chemotherapy-induced nausea and vomiting market by increasing costs of imported APIs, formulation excipients, transdermal delivery systems, and pharmaceutical packaging materials. Oncology care providers in North America and Europe are most affected due to dependence on imported branded antiemetics, while Asia-Pacific faces higher export-related manufacturing costs. These tariffs are raising drug prices and impacting affordability for patients. At the same time, they are encouraging domestic drug formulation, regional generic manufacturing, and increased investment in cost-effective antiemetic production capabilities.

The chemotherapy-induced nausea and vomiting (cinv) market research report is one of a series of new reports that provides chemotherapy-induced nausea and vomiting (cinv) market statistics, including chemotherapy-induced nausea and vomiting (cinv) industry global market size, regional shares, competitors with a chemotherapy-induced nausea and vomiting (cinv) market share, detailed chemotherapy-induced nausea and vomiting (cinv) market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (cinv) industry. This chemotherapy-induced nausea and vomiting (cinv) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy-induced nausea and vomiting (CINV) is a condition characterized by sensations of nausea and episodes of vomiting that may occur as a result of chemotherapy treatment. It is a common side effect experienced by many cancer patients and can significantly impact quality of life and treatment outcomes. CINV can be effectively managed through pharmacological therapies and supportive lifestyle measures.

The main forms of chemotherapy-induced nausea and vomiting (CINV) include injectable formulations, oral medications, and transdermal patches. Injectables are substances administered into the body to produce therapeutic effects. The major drug classes used to manage CINV include 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. Treatments are categorized based on emetogenic risk, including highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), and low emetogenic chemotherapy (LEC). These therapies are distributed through channels such as hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores and are applied across clinical areas including gynecology, urology, gastrointestinal surgery, and others.

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.